{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:21:19Z","timestamp":1771734079718,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff\u2019s assessment of patient symptom severity is often lower than patient self-reporting. This article reviews patient-reported outcome (PRO) assessment tools and their application in the field of multiple myeloma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the universal patient-reported outcome assessment tool most frequently used to evaluate the life quality in people with multiple myeloma. Among the specific patient-reported outcome assessment tools, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Multiple Myeloma Module (EORTC QLQ-MY20), the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), and the M.D. Anderson Symptom Inventory-Multiple Myeloma Module (MDASI-MM) are the most widely used, with some scholars using the EORTC QLQ-MY20 as a calibration correlate for scale development.<\/jats:p>\n                <jats:p>Most current assessment instruments were developed using classical measurement theory methods; future researchers could combine classic theory tests and item response theory to create scientific assessment instruments.<\/jats:p>\n                <jats:p>In addition, researchers select the appropriate assessment tool based on the purpose of the study. They can translate high-quality assessment tools into different languages and consider applying them more often to assessing multiple myeloma patients. Finally, most existing PROs focus on measuring life quality and symptoms in people with multiple myeloma, with less research on outcomes such as adherence and satisfaction, thus failing to comprehensively evaluate the patient treatment and disease management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Research has shown that the field of PROs in multiple myeloma is in an exploratory phase. There is still a need to enrich the content of PROs and develop more high-quality PRO scales for multiple myeloma based on the strengths and weaknesses of existing tools. With the successful advancement of information technology, PROs for people with multiple myeloma could be integrated with electronic information systems, allowing patients to report their health status in real time and doctors to track their condition and adjust their treatment, thereby improving patient outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-07902-4","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T07:02:36Z","timestamp":1688108556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment tools for patient-reported outcomes in multiple myeloma"],"prefix":"10.1007","volume":"31","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LeiWen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"7835","key":"7902_CR1","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1038\/d41586-020-03223-2","volume":"587","author":"B Owens","year":"2020","unstructured":"Owens B (2020) Outlook: Multiple myeloma. Nat 587(7835):S55. https:\/\/doi.org\/10.1038\/d41586-020-03223-2","journal-title":"Nat"},{"issue":"4","key":"7902_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3761\/j.issn.2096-7446.2022.04.008","volume":"3","author":"Z Yan","year":"2022","unstructured":"Yan Z, Liya Q, Rui C et al (2022) Identification and emergency care of sudden loss of consciousness in patients with multiple myeloma complicated with myocardial amyloidosis. Chin J Emerg Crit Care Nurs 3(4):335\u2013337. https:\/\/doi.org\/10.3761\/j.issn.2096-7446.2022.04.008","journal-title":"Chin J Emerg Crit Care Nurs"},{"issue":"5","key":"7902_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ (2022) What Is multiple myeloma? Jama 327(5):497. https:\/\/doi.org\/10.1001\/jama.2021.25306","journal-title":"Jama"},{"issue":"9","key":"7902_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A et al (2018) Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 4(9):1221\u20131227. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"issue":"8","key":"7902_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","volume":"24","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Hamilton BK, Hashmi SK et al (2018) Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 24(8):1546\u20131553. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"7902_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/jnci\/djac128","volume":"114","author":"MD Brundage","year":"2022","unstructured":"Brundage MD, Crossnohere NL, O\u2019Donnell J et al (2022) Listening to the patient voice adds value to cancer clinical trials. J Natl Cancer Inst 114(10):1323\u20131332. https:\/\/doi.org\/10.1093\/jnci\/djac128","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"7902_CR7","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.21.02163","volume":"39","author":"TL Kaufmann","year":"2021","unstructured":"Kaufmann TL, Rocque GB (2021) Pathway to precision patient-reported outcomes. J Clin Oncol 39(34):3770\u20133772. https:\/\/doi.org\/10.1200\/JCO.21.02163","journal-title":"J Clin Oncol"},{"issue":"6846","key":"7902_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM et al (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305(6846):160\u2013164. https:\/\/doi.org\/10.1136\/bmj.305.6846.160","journal-title":"BMJ"},{"issue":"5","key":"7902_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"J Catto","year":"2021","unstructured":"Catto J, Downing A, Mason S et al (2021) Quality of Life After bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol 79(5):621\u2013632. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.032","journal-title":"Eur Urol"},{"issue":"1","key":"7902_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bjh.17435","volume":"194","author":"T Plesner","year":"2021","unstructured":"Plesner T\uff0cDimopoulos M A\uff0cOriol A\uff0cet al. (2021) Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. Br J Haematol 194(1):132-139. https:\/\/doi.org\/10.1111\/bjh.17435","journal-title":"Br J Haematol"},{"issue":"5","key":"7902_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.jpainsymman.2018.01.016","volume":"55","author":"E Sprague","year":"2018","unstructured":"Sprague E, Siegert RJ, Medvedev O et al (2018) Rasch analysis of the Edmonton symptom assessment system. J Pain Symptom Manage 55(5):1356\u20131363. https:\/\/doi.org\/10.1016\/j.jpainsymman.2018.01.016","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"7902_CR12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jpainsymman.2015.05.018","volume":"50","author":"Y Dong","year":"2015","unstructured":"Dong Y, Chen H, Zheng Y et al (2015) Psychometric validation of the edmonton symptom assessment system in Chinese patients. J Pain Symptom Manage 50(5):712\u2013717. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.05.018","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"7902_CR13","doi-asserted-by":"publisher","first-page":"e714","DOI":"10.1016\/j.clovemylife.2021.05.002","volume":"21","author":"MS Ebraheem","year":"2021","unstructured":"Ebraheem MS, Seow H, Balitsky AK et al (2021) Trajectory of symptoms in patients undergoing autologous stem cell transplant for multiple myeloma: a population-based cohort study of patient-reported outcomes. Clin Lymphoma Myeloma Leuk 21(9):e714\u2013e721. https:\/\/doi.org\/10.1016\/j.clovemylife.2021.05.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"7902_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.2020.14205","volume":"324","author":"KL Quinn","year":"2020","unstructured":"Quinn KL, Shurrab M, Gitau K et al (2020) Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: a systematic review and meta-analysis. JAMA 324(14):1439\u20131450. https:\/\/doi.org\/10.1001\/jama.2020.14205","journal-title":"JAMA"},{"issue":"5","key":"7902_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jpainsymman.2015.05.014","volume":"50","author":"N Yokomichi","year":"2015","unstructured":"Yokomichi N, Morita T, Nitto A et al (2015) Validation of the Japanese Version of the Edmonton Symptom Assessment System-Revised. J Pain Symptom Manage 50(5):718\u2013723. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.05.014","journal-title":"J Pain Symptom Manage"},{"key":"7902_CR16","doi-asserted-by":"publisher","first-page":"n1647","DOI":"10.1136\/bmj.n1647","volume":"374","author":"R Maguire","year":"2021","unstructured":"Maguire R, McCann L, Kotronoulas G et al (2021) Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ 374:n1647. https:\/\/doi.org\/10.1136\/bmj.n1647","journal-title":"BMJ"},{"issue":"1","key":"7902_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpainsymman.2007.12.019","volume":"37","author":"KK Cheng","year":"2009","unstructured":"Cheng KK et al (2009) Measuring the symptom experience of Chinese cancer patients: a validation of the Chinese version of the memorial symptom assessment scale. J Pain Symptom Manage 37(1):44\u201357. https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.12.019","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"7902_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jpainsymman.2018.02.017","volume":"55","author":"I Llamas-Ramos","year":"2018","unstructured":"Llamas-Ramos I, Llamas-Ramos R, Buz J et al (2018) Construct validity of the Spanish versions of the Memorial Symptom Assessment Scale Short Form and Condensed Form: Rasch analysis of responses in oncology outpatients. J Pain Symptom Manage 55(6):1480\u20131491. https:\/\/doi.org\/10.1016\/j.jpainsymman.2018.02.017","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"7902_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jpainsymman.2007.12.008","volume":"36","author":"WW Lam","year":"2008","unstructured":"Lam WW, Law CC, Fu YT et al (2008) New insights in symptom assessment: the Chinese Versions of the Memorial Symptom Assessment Scale Short Form (MSAS-SF) and the Condensed MSAS (CMSAS). J Pain Symptom Manage 36(6):584\u2013595. https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.12.008","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"7902_CR20","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s00520-022-06896-9","volume":"30","author":"F Chen","year":"2022","unstructured":"Chen F, Leng Y, Ni J et al (2022) Symptom clusters and quality of life in ambulatory patients with multiple myeloma. Support Care Cancer 30(6):4961\u20134970. https:\/\/doi.org\/10.1007\/s00520-022-06896-9","journal-title":"Support Care Cancer"},{"key":"7902_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fphar.2020.01308","volume":"11","author":"P Goswami","year":"2020","unstructured":"Goswami P, Oliva EN, Ionova T et al (2020) Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): construct validity study. Front Pharmacol 11:1308. https:\/\/doi.org\/10.3389\/fphar.2020.01308","journal-title":"Front Pharmacol"},{"key":"7902_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fphar.2020.00209","volume":"11","author":"P Goswami","year":"2020","unstructured":"Goswami P, Oliva EN, Ionova T et al (2020) Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): content validity. Front Pharmacol 11:209. https:\/\/doi.org\/10.3389\/fphar.2020.00209","journal-title":"Front Pharmacol"},{"issue":"3","key":"7902_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","volume":"104","author":"ML Stead","year":"1999","unstructured":"Stead ML, Brown JM, Velikova G et al (1999) Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 104(3):605\u2013611. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01206.x","journal-title":"Br J Haematol"},{"issue":"11","key":"7902_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43(11):1670\u20131678. https:\/\/doi.org\/10.1016\/j.ejca.2007.04.022","journal-title":"Eur J Cancer"},{"issue":"11","key":"7902_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jval.2019.06.004","volume":"22","author":"F Efficace","year":"2019","unstructured":"Efficace F, Cottone F, Sommer K et al (2019) Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. Value Health 22(11):1303\u20131310. https:\/\/doi.org\/10.1016\/j.jval.2019.06.004","journal-title":"Value Health"},{"issue":"21","key":"7902_CR26","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1002\/cam4.3391","volume":"9","author":"X Li","year":"2020","unstructured":"Li X, Liu J, Chen M et al (2020) Health-related quality of life of patients with multiple myeloma: a real-world study in China. Cancer Med 9(21):7896\u20137913. https:\/\/doi.org\/10.1002\/cam4.3391","journal-title":"Cancer Med"},{"issue":"19","key":"7902_CR27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1200\/JCO.18.01006","volume":"37","author":"SH Ahmedzai","year":"2019","unstructured":"Ahmedzai SH, Snowden JA, Ashcroft AJ et al (2019) Patient-reported outcome results from the open-label, randomized phase III MYELOMA X Trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. J Clin Oncol 37(19):1617\u20131628. https:\/\/doi.org\/10.1200\/JCO.18.01006","journal-title":"J Clin Oncol"},{"issue":"8","key":"7902_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"X Leleu","year":"2018","unstructured":"Leleu X, Masszi T, Bahlis NJ et al (2018) Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol 93(8):985\u2013993. https:\/\/doi.org\/10.1002\/ajh.25134","journal-title":"Am J Hematol"},{"key":"7902_CR29","doi-asserted-by":"publisher","first-page":"651523","DOI":"10.3389\/fphar.2021.651523","volume":"12","author":"LP Silveira","year":"2021","unstructured":"Silveira LP, Menezes DPC, Drummond P et al (2021) Validation of an instrument for measuring adherence to treatment with immunomodulators in patients with multiple myeloma. Front Pharmacol 12:651523. https:\/\/doi.org\/10.3389\/fphar.2021.651523","journal-title":"Front Pharmacol"},{"key":"7902_CR30","doi-asserted-by":"publisher","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","volume":"12","author":"M Selvy","year":"2021","unstructured":"Selvy M, Kerckhove N, Pereira B et al (2021) Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study. Front Pharmacol 12:637593. https:\/\/doi.org\/10.3389\/fphar.2021.637593","journal-title":"Front Pharmacol"},{"key":"7902_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS et al (2013) Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13. https:\/\/doi.org\/10.1186\/1756-8722-6-13","journal-title":"J Hematol Oncol"},{"issue":"6","key":"7902_CR32","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","volume":"43","author":"LI Wagner","year":"2012","unstructured":"Wagner LI, Robinson DJ, Weiss M et al (2012) Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage 43(6):1094\u20131104. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.06.019","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"7902_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1186\/s12885-021-08453-9","volume":"21","author":"G Tremblay","year":"2021","unstructured":"Tremblay G, Daniele P, Breeze J et al (2021) Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer 21(1):993. https:\/\/doi.org\/10.1186\/s12885-021-08453-9","journal-title":"BMC Cancer"},{"issue":"3","key":"7902_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","volume":"18","author":"S Gupta","year":"2018","unstructured":"Gupta S, Abouzaid S, Liebert R et al (2018) Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 18(3):210\u2013218. https:\/\/doi.org\/10.1016\/j.clml.2018.01.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"7902_CR35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jpainsymman.2019.12.372","volume":"59","author":"CW Chan","year":"2020","unstructured":"Chan CW, Lee PH, Molassiotis A et al (2020) Symptom clusters in postchemotherapy neutropenic fever in hematological malignancy: associations among sickness behavior symptom cluster, inflammatory biomarkers of procalcitonin and c-reactive protein, and febrile measures. J Pain Symptom Manage 59(6):1204\u20131211. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.12.372","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"7902_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00520-020-05493-y","volume":"29","author":"M Kamal","year":"2021","unstructured":"Kamal M, Wang XS, Shi Q et al (2021) Symptom burden and its functional impact in patients with \u201csymptomatic\u201d relapsed or refractory multiple myeloma. Support Care Cancer 29(1):467\u2013475. https:\/\/doi.org\/10.1007\/s00520-020-05493-y","journal-title":"Support Care Cancer"},{"issue":"5","key":"7902_CR37","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-13-2442","volume":"20","author":"XS Wang","year":"2014","unstructured":"Wang XS, Shi Q, Shah ND et al (2014) Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366\u20131374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2442","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7902_CR38","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634\u20131646. https:\/\/doi.org\/10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","journal-title":"Cancer"},{"key":"7902_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12885-015-1261-6","volume":"15","author":"TR Osborne","year":"2015","unstructured":"Osborne TR, Ramsenthaler C, Schey SA et al (2015) Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer 15:280. https:\/\/doi.org\/10.1186\/s12885-015-1261-6","journal-title":"BMC Cancer"},{"issue":"5","key":"7902_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/0269216319833588","volume":"33","author":"C Ramsenthaler","year":"2019","unstructured":"Ramsenthaler C, Gao W, Siegert RJ et al (2019) Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study. Palliat Med 33(5):541\u2013551. https:\/\/doi.org\/10.1177\/0269216319833588","journal-title":"Palliat Med"},{"issue":"1","key":"7902_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12885-020-06730-7","volume":"20","author":"C Gerlach","year":"2020","unstructured":"Gerlach C, Taylor K, Ferner M et al (2020) Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer 20(1):245. https:\/\/doi.org\/10.1186\/s12885-020-06730-7","journal-title":"BMC Cancer"},{"issue":"12","key":"7902_CR42","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jval.2021.06.010","volume":"24","author":"KS Gries","year":"2021","unstructured":"Gries KS, Fastenau J, Seo C et al (2021) Development of the Multiple Myeloma Symptom and Impact Questionnaire: a new patient-reported outcome instrument to assess symptom and impacts in patients with multiple myeloma. Value Health 24(12):1807\u20131819. https:\/\/doi.org\/10.1016\/j.jval.2021.06.010","journal-title":"Value Health"},{"key":"7902_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C et al (2016) The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer 16:427. https:\/\/doi.org\/10.1186\/s12885-016-2410-2","journal-title":"BMC Cancer"},{"issue":"6","key":"7902_CR44","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois D et al (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24(6):976\u2013982. https:\/\/doi.org\/10.1200\/JCO.2005.04.0824","journal-title":"J Clin Oncol"},{"issue":"5","key":"7902_CR45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/eurjcn\/zvac020","volume":"21","author":"TH Nguyen","year":"2022","unstructured":"Nguyen TH, Lee CS, Kim MT (2022) Using item response theory to develop and refine patient-reported outcome measures. Eur J Cardiovasc Nurs 21(5):509\u2013515. https:\/\/doi.org\/10.1093\/eurjcn\/zvac020","journal-title":"Eur J Cardiovasc Nurs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07902-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T10:18:20Z","timestamp":1689329900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07902-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["7902"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07902-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"5 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"431"}}